Over the past several years, the healthcare industry as a whole has experienced an abundance of mergers and acquisitions – major players are buying up their peers in deals ranging from millions to billions. The trend is continuing, and the healthcare playing field continues to be shaped by these mega-transactions. For the medical device industry, […]
Edwards Lifesciences closes $690m Valtech Cardio buy
Edwards Lifesciences (NYSE:EW) said yesterday that it closed the $690 million buyout of Valtech Cardio and most of the heart valve repair technologies it’s developing. Valtech makes the Cardioband device, which is designed to reshape the mitral valve using specially designed anchors. The deal, announced in November 2016, calls for $340 million in up-front cash and another $350 million in milestones over 10 […]
Edwards Lifesciences to acquire Valtech Cardio in $690m deal
Edwards Lifesciences (NYSE:EW) said today that it agreed to put $690 million on the table for Valtech Cardio and most of the heart valve repair technologies it’s developing. The deal, which calls for $340 million in up-front cash and another $350 million in milestones, does not include Valtech Cardio’s transseptal mitral valve replacement program. That business is slated […]
Valtech touts German reimbursement win for Cardioband
Valtech Cardio said Tuesday it won reimbursement in Germany for its Cardioband Mitral Reconstruction System designed to treat mitral regurgitation in heart failure patients. The Cardioband system is composed of a reconstruction implant and a transfemoral, transseptal delivery system. The suture-less implant is connected to the mitral annulus using specially designed anchors, and the mitral […]
HeartWare shareholder threatens proxy fight over Valtech merger
HeartWare International (NSDQ:HTWR) may face a proxy battle from a shareholder over its proposed acquisition of Israeli replacement heart valve maker Valtech Cardio, according to an SEC filing posted yesterday. The company said it received a notice from shareholding firm Engaged Capital nominating 3 board members and opposing its proposed acquisition of Valtech. “While we […]
HeartWare clears final anti-trust hurdle on Valtech Cardio buy
HeartWare International (NSDQ:HTWR) said today that it’s past the waiting period required to satisfy U.S. anti-trust regulations for its pending acquisition of Israeli replacement heart valve maker Valtech Cardio. That marks the final anti-trust hurdle for the deal, which must still be approved by the companies’ shareholders. HTWR shares, off -44% since the deal’s Sept. 1 announcement, rose […]
Activist investor fights HeartWare’s $766m Valtech buy
Activist investor Engaged Capital, a recent backer of HeartWare International (NSDQ:HTWR), is trying to block the implantable heart pump maker’s $766 million buyout of Valtech Cardio. The deal for Valtech calls for an up-front payment of 4.4 million shares of HeartWare stock, plus potential milestones of 800,000 shares when Valtech’s Cardioband annuloplasty device wins CE Mark approval in […]
Valtech Cardio wins CE Mark for Cardioband mitral repair device
Valtech Cardio, which agreed to be acquired by HeartWare International (NSDQ:HTWR) earlier this month, today said it won CE Mark approval in the European Union for its Cardioband mitral valve repair device. Or Yehuda, Israel-based Valtech said it plans to unveil the Cardioband device at the PCR London Valves meeting in Berlin next week. “We are […]
HeartWare plunges on Valtech Cardio buyout
Shares of HeartWare International (NSDQ:HTWR) plunged 20.8% after the company announced a buyout of Israeli replacement heart valve maker Valtech Cardio. HTWR shares closed at $64.82 apiece yesterday as investors reacted to the highly dilutive terms of the deal, which was worth some $929 million based on HeartWare’s closing price the day before it was announced. It’s now worth about […]
HeartWare inks $929m deal for Valtech Cardio’s mitral and tricuspid valves
HeartWare International (NSDQ:HTWR) said yesterday that it agreed to put roughly $929 million on the table for Israeli replacement heart valve maker Valtech Cardio. Terms of the deal call for an up-front payment of 4.4 million shares of HeartWare stock, which would be worth about $360 million at yesterday’s closing price of $81.81. The buyout also […]
Positive early data for Valtech’s Cardioband
A trial of Valtech Cardio‘s Cardioband transcatheter annuloplasty system showed no device-related mortality, with decreases in mitral regurgitation and septo-lateral dimension. Results from the 40-patient multicenter observational study, designed to evaluate the safety and performance of the Cardioband, were presented this week at the European Society of Cardiology’s annual meeting in Paris. The study was […]
MassDevice Network
@MassDevice
LinkedIn
YouTube